Kirk Jeremy M W, Wickramasuriya Nalin, Shaw Nicholas J
Department of Endocrinology, Birmingham Children's Hospital , Steelhouse Lane, Birmingham, B4 6NH , UK.
Endocrinol Diabetes Metab Case Rep. 2016;2016:150096. doi: 10.1530/EDM-15-0096. Epub 2016 Jan 6.
Estrogen is used to induce puberty in peripubertal girls with hypogonadism. Although both synthetic and natural forms are available, along with different routes of administration, in the UK oral ethinyl estradiol and the low-dose oral contraceptive pill are commonly used as hormone replacement therapy for practical reasons. We present five peripubertal girls (aged 12.5-14.9 years) with hypogonadism (two with primary hypogonadism due to Turner syndrome and three with central (secondary) hypogonadism as part of multiple pituitary hormone deficiency) who for a variety of reasons have received milligram doses of estradiol (E2) in error for between 6 weeks and 6 months, instead of the expected microgram doses of ethinyl estradiol. Although there are no direct comparisons in peripubertal girls between synthetic and natural estrogens, all girls had vaginal bleeding whilst receiving the milligram doses and have ended up with reduced final heights, below the 9th centile in 1 and below the 2nd centile in 4. Whilst reduction in final height may be part of the underlying condition (especially in Turner syndrome) the two girls with height predictions performed prior to receiving the estrogen overdose have not achieved their predicted height. Estrogen is one of the few drugs which is available in both milligram and microgram formulations. Clinicians need to be alert to the possibility of patients receiving the wrong formulation and dosage in error.
Girls with primary and secondary gonadal failure require assistance with pubertal induction.Although several different formulations and route of administration are available, for practical reasons, the majority of girls in the UK receive oral ethinyl estradiol.Estrogen preparations are available in both milligram and microgram formulations, with potential for receiving the wrong dose.Girls receiving milligram rather than microgram preparations all had vaginal bleeding and a short final height.
雌激素用于诱导性腺功能减退的青春期前女孩进入青春期。尽管合成和天然形式的雌激素都有,且给药途径不同,但在英国,出于实际原因,口服炔雌醇和低剂量口服避孕药通常被用作激素替代疗法。我们报告了5名青春期前女孩(年龄12.5 - 14.9岁)患有性腺功能减退(2名因特纳综合征导致原发性性腺功能减退,3名因多种垂体激素缺乏导致中枢性(继发性)性腺功能减退),她们由于各种原因错误地接受了毫克剂量的雌二醇(E2),持续时间为6周至6个月,而不是预期的微克剂量的炔雌醇。虽然在青春期前女孩中没有对合成雌激素和天然雌激素进行直接比较,但所有女孩在接受毫克剂量时都出现了阴道出血,最终身高降低,其中1名低于第9百分位,4名低于第2百分位。虽然最终身高降低可能是潜在疾病的一部分(尤其是在特纳综合征中),但在接受过量雌激素之前进行身高预测的两名女孩并未达到她们的预测身高。雌激素是少数有毫克和微克两种剂型的药物之一。临床医生需要警惕患者错误地接受错误剂型和剂量的可能性。
原发性和继发性性腺功能衰竭的女孩在青春期诱导方面需要帮助。尽管有几种不同的剂型和给药途径,但出于实际原因,英国大多数女孩接受口服炔雌醇。雌激素制剂有毫克和微克两种剂型,有可能接受错误的剂量。接受毫克而非微克制剂的女孩均出现阴道出血且最终身高较矮。